• Drug delivery - improving delivery of biopharmaceuticals by making them available without needles, either in tablet form or through the skin.
  
  
• New biopharmaceuticals - better versions of protein-based drugs by using natural human (hcx™) proteins, ensuring the presence of human attachments such as glycosylation.

Apollo's oral (Oradel™) and transdermal (TransD™) delivery platforms are unique in being able to deliver water and oil soluble molecules up to antibody size in a tablet or topical application. This will improve patient convenience and comfort compared to existing bio-drugs using proteins, which can only be delivered by needles.

Apollo's extensive library of natural human proteins (hcx™) provide a bank of bio-drug candidates that are expected to offer therapeutic advantages in terms of safety and effectiveness, because they more naturally mimic proteins in the human body.

Apollo is using these proteins to develop a range of superior biopharmaceuticals with the potential to transform treatment across many diseases and disorders, including:

• Hepatitis C
• Multiple sclerosis
• Rheumatoid arthritis
• Psoriasis
• Alzheimer's Disease
• Neuroprotection for stroke.

Apollo is also focused on providing improved lifestyle and convenience for patients using proprietary technology platforms that allow needle-free delivery of protein and antibody based drugs. The combined technologies are expected to lead to more effective and lower cost solutions compared to synthetic chemical drugs, while improving drug efficacy.